Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.72 USD
Change Today +0.05 / 0.75%
Volume 1.2M
OREX On Other Exchanges
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/15 - $9.37
52 Week Low
10/13/14 - $3.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

orexigen therapeutics inc (OREX) Related Businessweek News

View More BusinessWeek News

orexigen therapeutics inc (OREX) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products in the United States. The company offers Contrave for the treatment of obesity. It has a collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize Contrave in Canada and Mexico. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California.

47 Employees
Last Reported Date: 02/27/15
Founded in 2002

orexigen therapeutics inc (OREX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $640.6K
Chief Business & Financial Officer and Treasu...
Total Annual Compensation: $379.3K
Head of Global Development and Executive Vice...
Total Annual Compensation: $379.3K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $379.3K
Compensation as of Fiscal Year 2014.

orexigen therapeutics inc (OREX) Key Developments

Brower Piven Announces Commencement of Lawsuit Against Orexigen Therapeutics

The securities litigation law firm of Brower Piven announced that a class action lawsuit has been commenced in the United States District Court for the Southern District of California on behalf of purchasers of Orexigen Therapeutics, Inc. securities during the period between March 3, 2015 and March 5, 2015, inclusive. Investors who wish to become proactively involved in the litigation have until May 11, 2015 to seek appointment as lead plaintiff.

Orexigen Therapeutics, Inc. Announces Executive Changes

Orexigen Therapeutics, Inc. announced that Tom Cannell has joined as Chief Commercial Officer. As the company prepares for global commercialization of Contrave /Mysimba (naltrexone HCl /bupropion HCl extended release), Cannell will lead all aspects of Orexigen's global commercial strategy, assuming responsibilities previously held by Mark Booth. After successfully leading Orexigen's commercial effort through the U.S. launch of Contrave, Booth plans to leave Orexigen later this year to pursue opportunities closer to his home in Chicago. Cannell joins Orexigen after 27 years at Merck where he held a variety of senior leadership roles. He brings strong experience in global commercialization, consumer marketing, and sales operations and management. Recent assignments have included President of Merck Canada and Head of Marketing and Strategy for MSD Japan. Earlier he served in general manager roles for a U.S. sales division and as leader of a Merck business unit, managing a multi-billion dollar product portfolio and thousands of employees. He has strong consumer experience, having served as General Manager, New Commercial Model, U.S., where he designed and successfully piloted an innovative customer centric commercial model for Merck's U.S. business.

European Commission Grants Marketing Authorization for Orexigen Therapeutics's Mysimba™

Orexigen Therapeutics, Inc. announced that the European Commission has granted marketing authorization for Mysimba™ (naltrexone HCl /bupropion HCl prolonged release) as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (=18 years) with an initial Body Mass Index (BMI) of = 30 kg/m2 (obese), or = 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). This authorization applies to all 28 European Union (EU) member states.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $6.72 USD +0.05

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Arena Pharmaceuticals Inc $4.31 USD -0.03
GlaxoSmithKline PLC 1,521 GBp +9.50
Novo Nordisk A/S kr376.80 DKK -4.90
VIVUS Inc $2.31 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.8x
Price/Book 36.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 9.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at